Skip to content

Released Mar 26, 2026, before the open

10-K filed Mar 26, 2026, 85 days after period end · 0001628280-26-021413

Q4 2025 · 10-K

derived · Computed from the longer spans the company filed.

Revenue—
Net Income-$25.14MderivedN/M vs Q4 2024N/M vs Q3 2025
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$25,199,000N/M
Operating Cash Flowderived-$19,096,000N/M
Free Cash Flowderived-$19,096,000N/M

What the release said

The release

Same quarter

MetricQ4 2025derived from reported figuresQ4 2024derived from reported figuresQ4 2023derived from reported figuresQ4 2022derived from reported figures
Net Income-$25.14M-$37.15M-$16.50M-$12.87M

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR